

LIST OF TABLES

SR. NO.	TITLE	PAGE NO
1.1	Important validation parameters suggested by regulatory agencies	13
1.2	System suitability test parameters and recommendations	17
5.1.1.1	Optimization of hplc method	64
5.1.1.2	Regression analysis of the calibration curves for betamethasone dipropionate and butenafine hydrochloride.	65
5.1.1.3	Recovery studies of betamethasone dipropionate and butenafine hydrochloride	65
5.1.1.4	Precision of betamethasone dipropionate and butenafine hydrochloride	66
5.1.1.5	The intermediate precision of betamethasone dipropionate and butenafine hydrochloride	66
5.1.1.6	Robustness studies hplc method of betamethasone dipropionate and butenafine hydrochloride	67
5.1.1.7	System suitability test parameters for betamethasone dipropionate and butenafine hydrochloride	67
5.1.1.8	Analysis cream formulation	68
5.1.1.9	Summary of validation parameters for the proposed hplc method for betamethasone dipropionate and butenafine hydrochloride	69
5.1.2.1	Optimization of the method	74
5.1.2.2	Regression analysis of the calibration curves for escitalopram oxalate and etizolam	74
5.1.2.3	Recovery study of escitalopram oxalate and etizolam.	75
5.1.2.4	Precision study of escitalopram oxalate and etizolam hplc method.	75
5.1.2.5	Intraday precision of escitalopram oxalate and etizolam hplc method.	75
5.1.2.6	Intermediate precision of escitalopram oxalate and etizolam hplc method.	76
5.1.2.7	Robustness of escitalopram oxalate and etizolam hplc method.	77
5.1.2.8	System suitability test parameters for escitalopram oxalate and etizolam	77
5.1.2.9	Analysis of marketed tablet sample	78
5.1.2.10	Summary of validation parameters for the proposed hplc method for escitalopram oxalate and etizolam.	79
5.1.3.1	Optimization of method	84
5.1.3.2	Regression analysis of the calibration curves for escitalopram oxalate and etizolam	86
5.1.3.3	Recovery study of escitalopram oxalate and etizolam	87
5.1.3.4	Precision study of escitalopram oxalate and etizolam hplc method.	87
5.1.3.5	Intraday precision study of escitalopram oxalate and etizolam hplc method.	87
5.1.3.6	Intermediate precision study of escitalopram oxalate and etizolam hplc method	88

5.1.3.7	System suitability test parameters for escitalopram oxalate and etizolam	89
5.1.3.8	Analysis of marketed tablet sample	89
5.1.3.9	Summary of validation parameters for the proposed hplc method for escitalopram oxalate and etizolam	89
5.1.3.10	Purity and peak threshold for various stress conditions	91
5.1.5.1	Optimization of method	98
5.1.5.2	Regression analysis of the calibration curves for fluocinolone acetonide and miconazole nitrate	100
5.1.5.3	Recovery study of fluocinolone acetonide and miconazole nitrate	102
5.1.5.4	Precision study of fluocinolone acetonide and miconazole nitrate	103
5.1.5.5	Intraday precision study of fluocinolone acetonide and miconazole nitrate	103
5.1.5.6	Intermediate precision study of fluocinolone acetonide and miconazole nitrate	103
5.1.5.7	Robustness study of fluocinolone acetonide and miconazole nitrate	104
5.1.5.8	System suitability test parameters for fluocinolone acetonide and miconazole nitrate	105
5.1.5.9	Summary of validation parameters for the proposed hplc method for fluocinolone acetonide and miconazole nitrate	105
5.1.6.1	Optimization of the method	109
5.1.6.2	Regression analysis of the calibration curves for hydrocortisone acetate and miconazole nitrate	111
5.1.6.3	System suitability test parameters for hydrocortisone acetate and miconazole nitrate	114
5.1.6.4	Summary of validation parameters for the proposed hplc method for hydrocortisone acetate and miconazole nitrate	115
5.1.7.1	Optimization of the method.	118
5.1.7.2	Accuracy of racecadotril hplc method	119
5.1.7.3	Regression analysis of the calibration curves for racecadotril	120
5.1.7.4	Precision of the racecadotril hplc method	120
5.1.7.5	Intermediate precision of the racecadotril hplc method	121
5.1.7.6	Robustness study of the racecadotril hplc method	121
5.1.7.7	Summary of validation parameters for the proposed hplc method for Racecadotril	121
5.1.7.8	System suitability test parameters for Racecadotril	122
5.1.7.9	Summary of forced degradation study	122
5.2.1.1	Optimization of the method	127
5.2.1.2	Regression analysis of the calibration curves for ivermectin and butenafine hydrochloride.	129
5.2.1.3	Summary of validation parameters for the proposed hplc method for ivermectin and albendazole	130
5.2.2.1	Optimization of the mobile phase	133
5.2.2.2	Regression analysis of the calibration curves for butenafine hydrochloride and butenafine hydrochloride.	136

5.2.2.3	Summary of validation parameters for the proposed hptlc method for butenafine hydrochlorideand betamethasone dipropionate	136
---------	---	-----